Pasithea Therapeutics宣布在晚期癌症患者中完成Pas-004的第7组阶段I临床试验,取得积极的安全性、药代动力学(Pk)和药效动力学(Pd)数据
Pasithea Therapeutics宣布在晚期癌症患者中完成Pas-004的第7组阶段I临床试验,取得积极的安全性、药代动力学(Pk)和药效动力学(Pd)数据
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.